Medifast (NYSE:MED) Releases Q2 2025 Earnings Guidance

Medifast (NYSE:MED) updated its second quarter 2025 earnings guidance on Monday. The company provided earnings per share guidance of -0.550-0.000 for the period, compared to the consensus earnings per share estimate of -0.070. The company issued revenue guidance of $85.0 million-$105.0 million, compared to the consensus revenue estimate of $112.3 million.

Analysts Set New Price Targets

Separately, DA Davidson dropped their price objective on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating for the company in a research note on Wednesday, February 19th.

Medifast Stock Down 4.2 %

Shares of Medifast stock traded down $0.53 on Tuesday, hitting $12.05. 44,772 shares of the company’s stock traded hands, compared to its average volume of 318,981. Medifast has a 52-week low of $11.57 and a 52-week high of $36.30. The stock has a market cap of $131.80 million, a P/E ratio of 66.94 and a beta of 1.05. The firm’s 50-day moving average is $13.51 and its 200 day moving average is $16.10.

Medifast (NYSE:MED) last posted its quarterly earnings results on Monday, April 28th. The specialty retailer reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The business had revenue of $115.73 million during the quarter, compared to analyst estimates of $114.85 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%. Equities research analysts forecast that Medifast will post 0.51 EPS for the current year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.